Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

amgen

POPULAR ARTICLES

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

LATEST ARTICLES

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

/C O R R E C T I O N -- Amgen/

/C O R R E C T I O N -- Amgen/

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

Latest News

Homeland Nickel Engages Investor Relations Consultant

Homerun Resources Inc. Announces Binding Distribution Agreement with Cristal Sand Group, Securing First Commercial Sales of High-Purity Industrial Silica Sand from Santa Maria Eterna

Brixton Metals Graduates To Trading On The OTCQX

Lahontan Closes Second Tranche of Private Placement for an Aggregate of $11.7M

Nuvau Launches 17,500-Metre Drill Program at Matagami

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Precipitate Gold

Precipitate Gold (PRG:CC)

PRG:CC

Uranium American Resources

UARI

Nuvau Minerals

Nuvau Minerals (NMC:CC)

NMC:CC

Mayfair Gold Corp.

Mayfair Gold Corp. (MFG:CC)

MFG:CC

Canada One Mining

Canada One Mining (CONE:CC)

CONE:CC

Generation Uranium

Generation Uranium (GEN:CC)

GEN:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES